Ask AI

Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs

Improve your understanding of established and novel HER2-targeted ADCs to manage advanced bladder cancer based on the latest evidence and guidelines through a certified on-demand webcast, expert-written ClinicalThought commentary, and downloadable slides. 

Share

Program Content

Activities

Treatment of HER2 Positive Advanced Bladder Cancer
Personalizing Treatment of HER2-Positive Advanced Bladder Cancer: Expert Guidance on the Latest Evidence for HER2-Targeted ADCs
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.